comparison of intravenous iron preparations to treat iron-deficiency anemia in antepartum women

Randomised control study of intravenous ferric carboxymaltose versus iron sucrose in treatment of iron deficiency anemia among antepartum women

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/07/044023

Enrollment

Registered

2022-07-14

Start date

Unknown

Completion date

Unknown

Last updated

2022-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O990- Anemia complicating pregnancy, childbirth and the puerperium

Interventions

Intervention1: intravenous ferrous carboxy-maltose: ferrous carboxy-maltose to be given intravenously in a single dose calculated by ganzonis formula. maximum dose 1000mg/week. iv preparation tobe giv

Eligibility

Inclusion criteria

Inclusion criteria: pregnant women between gestation age 16-34 weeks with Hb between 7-9.9 gm/dl and failed oral supplementation therapy of iron.

Exclusion criteria

Exclusion criteria: pregnant patients with allergy to iron therapy previously, known medical illness such as asthma, thromboembolism, requiring emergency cesarean section and negative consent. patient who requires blood transfusion for severe anemia

Design outcomes

Primary

Measure	Time frame
to measure the improvement in hematological parameters such as Hb, RBC indices and serum ferritin between group A and group BTimepoint: 6 weeks	—

Secondary

Measure	Time frame
adverse effects and side effectsTimepoint: 6 weeks	—

Countries

India

Contacts

Public ContactVinita Gupta

Dept. of Obstetrics & Gynecology Dr. Baba Saheb Ambedkar Medical College and Hospital

vinitagupta24@gmail.com9560773962

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026